Concall Intelligence
Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search official call evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.
Management evidence
Generated 22 Oct, 12:17 am IST · click a summary to inspect source-linked evidence for this results quarter.
| Company | Call and sources | Reported result | Management outlook | Evidence-led conclusion | Review |
|---|---|---|---|---|---|
| INDIANB Indian Bank Financial Services · Mid | Sept 2026 21 Oct 2026 Transcript verified | Good 60/100 | Optimistic outlook Broadly unchanged Guidance raised | Indian Bank reported a strong set of results for Q2 FY27 with net profit growing 14.71% YoY to Rs.3,462 crore (aided by NSE listing gains), healthy advances growth of 16.39%, and improving asset quality metrics with GNPA at 1.61%. Management has revised its deposit and advances growth guidance upwards for the full year while acknowledging potential headwinds from regulatory changes, potential HTM valuation shocks, and credit cost normalisation under ECL models. Evidence summary ready | |
| HDBFS HDB Financial Services Limited Financial Services · Large | Sept 2026 20 Oct 2026 Transcript verified | Good 55/100 | Optimistic outlook Broadly unchanged No measurable guidance | HDB Financial Services delivered strong top‑line and profit growth in Q2 FY27, driven by robust disbursements across enterprise and consumer segments, improved asset quality and margins, and continued capital strength. Management is optimistic about H2, citing festive demand and capacity to scale, but flags monsoon‑related inflation, seasonal asset‑quality pressures and regulatory fee uncertainties as risks. Evidence summary ready | |
| ICICIGI ICICI Lombard General Insurance Company Limited Financial Services · Mid | Sept 2026 19 Oct 2026 Transcript filed | Result pending No matching current-quarter result row | Outlook pending No comparable prior call Guidance pending | The available source has not produced sufficient structured evidence. Summary pending | |
| METROPOLIS Metropolis Healthcare Limited Pharma · Micro | Sep 2026 19 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call No measurable guidance | Management projects continued profitable and sustainable growth, leveraging technology, science, and network expansion. Focus on specialty tests, TruHealth, and D2C channels, alongside strategic M&A, aims to outpace industry growth and create shareholder value. Evidence summary ready | |
| NOVARTIND Novartis India Limited Pharma · Small | Sep 2026 19 Oct 2026 Transcript filed | Result pending No matching current-quarter result row | Outlook pending No comparable prior call Guidance pending | The available source has not produced sufficient structured evidence. Summary pending | |
| HTEL Hy-Tech Engineers Limited Industrials · Micro | Sep 2026 19 Oct 2026 Transcript filed | Result pending No matching current-quarter result row | Outlook pending No comparable prior call Guidance pending | The available source has not produced sufficient structured evidence. Summary pending | |
| ASTERDM Aster DM Healthcare Limited Pharma · Small | Sep 2026 19 Oct 2026 Transcript verified | Result pending No matching current-quarter result row | Optimistic outlook Broadly unchanged No measurable guidance | The successful merger and strong proforma FY2026 results, coupled with clear strategic priorities for integration and network expansion, suggest the company is on track to leverage scale and clinical depth. Management's focus on capital efficiency and margin improvement supports the long-term value creation thesis. Evidence summary ready | |
| HCLTECH HCL Technologies Limited IT · Large | Sept 2026 15 Oct 2026 Transcript verified | Good 70/100 | Cautious outlook Broadly unchanged Guidance maintained | HCLTech delivered solid top‑line growth and margin expansion, driven by strong Advanced AI services and record bookings, while software revenue declined and margin guidance remains cautious. Evidence summary ready | |
| CENTUM Centum Electronics Limited Industrials · Small | Sep 2026 10 Oct 2026 Preliminary brief | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call No measurable guidance | The investment thesis remains intact as Centum continues to scale its high-margin Build-to-Specification (BTS) business alongside its stable EMS cash engine. The company boasts a strong total order book of INR 18 billion, improving ROCE to 21% in FY26, and strong structural tailwinds from domestic indigenization and China+1 supply chain diversification. Evidence summary ready | |
| COCHINSHIP Cochin Shipyard Limited Industrials · Mid | Sep 2026 10 Oct 2026 Preliminary brief | Result pending No matching current-quarter result row | Optimistic outlook No comparable prior call No measurable guidance | The company demonstrates strong order book visibility, supported by significant capacity expansion projects recently commissioned and others in the pipeline. Strategic JVs and acquisitions are aimed at diversifying capabilities and market reach, suggesting continued growth momentum. Evidence summary ready | |
| WABAG VA Tech Wabag Limited Infra · Micro | Sept 2026 7 Oct 2026 Transcript filed | Result pending No matching current-quarter result row | Outlook pending No comparable prior call Guidance pending | The available source has not produced sufficient structured evidence. Summary pending | |
| RATEGAIN Rategain Travel Technologies Limited IT · Micro | Sept 2026 6 Oct 2026 Transcript filed | Result pending No matching current-quarter result row | Outlook pending No comparable prior call Guidance pending | The available source has not produced sufficient structured evidence. Summary pending |